Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).

@article{Byrd2002PretreatmentCA,
  title={Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).},
  author={J. Byrd and K. Mr{\'o}zek and R. Dodge and A. Carroll and C. Edwards and D. Arthur and M. Pettenati and S. Patil and Kathleen W. Rao and M. Watson and P. Koduru and Joseph O. Moore and R. Stone and R. Mayer and E. Feldman and F. Davey and C. Schiffer and R. Larson and C. Bloomfield},
  journal={Blood},
  year={2002},
  volume={100 13},
  pages={
          4325-36
        }
}
We analyzed prospectively 1213 adults with de novo acute myeloid leukemia (AML) to ascertain the prognostic impact of cytogenetic abnormalities on complete remission (CR) rate, 5-year cumulative incidence of relapse (CIR), and 5-year overall survival (OS). All patients received similar induction therapy. Median follow-up for surviving patients was 8.3 years. Nonprioritized cytogenetics distinguished t(8;21) and inv(16)/t(16;16) as conferring a significantly better prognosis than normal… Expand

Paper Mentions

Interventional Clinical Trial
Evaluate the safety and tolerability of pegcrisantaspase in combination with venetoclax (Ven-PegC) and estimate the maximum tolerated doses and/or biologically active doses of… Expand
ConditionsRelapsed or Refractory Acute Myeloid Leukemia
InterventionDrug
Interventional Clinical Trial
Primary study objective is the evaluation of efficacy of autologous hematopoietic cell transplantation (HCT) with core-binding factor (CBF) positive acute myeloid leukemia (AML) in… Expand
ConditionsLeukemia, Myeloid
InterventionProcedure
Interventional Clinical Trial
Pilot, multicentric, open-label, single-arm, phase I-II clinical trial to evaluate the safety and efficacy of a novel Umbilical Cord Blood Transplantation (UCBT) platform, that consists… Expand
ConditionsLeukemia
InterventionOther
Interventional Clinical Trial
[Study Objectives] - To evaluate the efficacy of allogeneic hematopoietic cell transplantation (HCT) in patients with acute lymphoblastic leukemia (ALL) in the first or… Expand
ConditionsAcute Lymphoid Leukemia
InterventionProcedure
Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation.
  • Yiming Chen, J. Cortes, +11 authors F. Ravandi
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 77 REFERENCES
Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients
...
1
2
3
4
5
...